Medical device company IMBiotechnologies has signed a supply agreement with group purchasing organization Medicus Management, which currently supplies 20 office-based laboratories and ASCs.
IMBiotechnologies' core product, Ekobi Embolization Microspheres, is a biodegradable embolic agent that is detectable by ultrasound and approved in the U.S. to treat inoperable hypervascularized tumors, according to a June 12 press release.
Medicus was founded by a group of physicians and partners with vascular ASCs and office-based labs.